
Artiva Biotherapeutics, Inc. — Investor Relations & Filings
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell-based therapies. The company's mission is to create effective, safe, and accessible cell therapies for patients with autoimmune diseases and cancer. Its lead product candidate, AlloNK® (AB-101), is a non-genetically modified, cryopreserved NK cell therapy. AlloNK® is being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for the treatment of autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and for various cancers. Artiva aims to overcome the limitations of complex and costly patient-specific cell therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-24 | English | |
| 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-20 | English | |
| 8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | |
| 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | |
| 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | |
| 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
8 filings
| |||||
| 32898860 | 8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-24 | English | ||
| 32898854 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-20 | English | ||
| 32898861 | 8-K - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
| 32898855 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
| 32898856 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
| 32898857 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
| 32898859 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
| 32898858 | 4 - ARTIVA BIOTHERAPEUTICS, INC. (0001817241) (Filer) | 2026-02-19 | English | ||
|
2025
7 filings
| |||||
| 13270649 | 4 | 2025-12-15 | English | ||
| 13270650 | Regulatory Filings 2025 | 2025-12-15 | English | ||
| 13270651 | 4 | 2025-12-12 | English | ||
| 13270652 | 4 | 2025-12-12 | English | ||
| 13270653 | 4 | 2025-12-12 | English | ||
| 13270654 | 4 | 2025-12-12 | English | ||
| 13270655 | 8-K | 2025-12-12 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Artiva Biotherapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34393/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34393 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34393 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34393 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34393}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Artiva Biotherapeutics, Inc. (id: 34393)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.